tapebrief
STE · Q4 2025
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

STE · Q1 2026 Earnings

Steris

Reported August 6, 2025

30-second summary

Steris delivered Q1 FY2026 revenue of $1.39B (+8.7% YoY) and non-GAAP EPS of $2.34, with AST accelerating to +12.6% and Life Sciences capital orders inflecting after a 16-month trough. Management raised as-reported FY2026 revenue guidance to 8–9% (from 6–7%) and free cash flow to $820M (from $770M), but reaffirmed EPS at $9.90–$10.15 — the FX tailwind is funding a $15M increase in the tariff drag (now $45M, up from $30M) plus higher healthcare benefit costs, not flowing to the bottom line.

Headline numbers

EPS

Q1 FY2026

$2.34

Revenue

Q1 FY2026

$1.39B

+8.7% YoY

Gross margin

Q1 FY2026

45.2%

Free cash flow

Q1 FY2026

$0.33B

Operating margin

Q1 FY2026

17.7%

Key financials

Q1 FY2026
MetricQ1 FY2026YoYQ4 FY2025QoQ
Revenue$1.39B+8.7%$1.48B-6.1%
EPS$2.34—$2.74-14.6%
Gross margin45.2%—43.3%+190bps
Operating margin17.7%—14.6%+310bps
Free cash flow$0.33B———

Guidance

Company raised FY2026 as-reported revenue guidance to 8-9% (from 6-7%) driven by 200bps of FX tailwinds, while reaffirming adjusted EPS at $9.90–$10.15 despite raising tariff headwind estimate from $30M to $45M.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
As reported revenue growth
FY 2026
6-7%8-9%+200 basis points at midpoint (from 6.5% to 8.5%)Raised
Free cash flow
FY 2026
$770 million$820 million+$50 million (+6.5%)Raised
Tariff impact on pre-tax profit
FY 2026
~$30 million reduction~$45 million reduction-$15 million headwind (50% increase in estimated tariff drag)Lowered

Reaffirmed unchanged this quarter: Constant currency organic revenue growth (6-7%), Capital expenditures ($375 million), Adjusted EPS ($9.90–$10.15)

Segment KPIs

Q1 FY2026
SegmentQ1 FY2026YoY
Healthcare$0.975B+8.1%
Applied Sterilization Technologies (AST)$0.281B+12.6%
Life Sciences$0.135B+5.2%
Healthcare Service Revenue Growth+13%—
AST Capital Equipment Revenue Growth+46%—

Other KPIs

Q1 FY2026
SegmentQ1 FY2026
Service Revenue$700.6M
Consumables Revenue$435.0M
Recurring Revenue$1,135.6M
Capital Equipment Revenue$255.5M
Total Backlog$514.5M
Operating Cash Flow$420.0M

Management tone

Narrative arc: Q4 FY2025 bioprocessing recovery, tariffs manageable → Q1 FY2026 bioprocessing normalized, tariffs worse but absorbed.

Bioprocessing has moved from "let's be conservative" to "fairly predictable." Last quarter management explicitly tempered the recovery framing, saying "let's take a little more conservative approach on how aggressively some of the bioprocessing is going to recover." This quarter the language inverts: "it's been pretty consistent now for, I would say, the last four or five months… we've gone back to what we would see as a normal trajectory off of a reset base. So we believe at this point it's fairly predictable." The Life Sciences print (+5.2% vs. -6.9% prior quarter) validates the shift, and the 16-month capital order trough is described as complete with backlog up over 50% to $111M in that sub-segment.

Tariff framing escalated from "active mitigation required" to "unprecedented escalation absorbed." Last quarter management introduced a $30M net headwind with the caveat that the gross was "significantly higher." This quarter the net headwind itself moved to $45M — a 50% increase — with management attributing the delta to specific policy changes: "the increased tariffs on metals… copper 0% to 50%, steel and aluminum 25% to 50%, are changes since then, and that's why we are increasing and not decreasing our tariff exposure." That the EPS guide held flat despite the $15M deterioration is the silent operational outperformance signal.

AST conservatism widens despite a Q1 acceleration. AST grew 12.6% versus a full-year guide of 6–7%, and management was explicit: "Despite the strong start, we are maintaining our outlook for the year at this time… I would say it's general conservatism. There's some moving parts going on in MedTech." For a segment now running at double the guided rate, holding the line is either prudent hedging against MedTech relocation timing or a deliberate sandbag — likely both.

The tone overall is more circumspect than the numbers warrant. EPS is set to grow 7–10%, FCF guidance just went up $50M, every segment beat trajectory, and the recurring revenue mix is strengthening — yet management leaned on phrases like "we'll see how things play out" and "It's hard to predict." That gap between print quality and verbal confidence is the most striking feature of the quarter.

Recurring themes management leaned on this quarter:

Tariff cost escalation and FX offset dynamicsBioprocessing demand normalization after volatilityLife sciences capital order cycle recovery from 16-month troughAST segment outperformance amid MedTech relocationHealthcare capital equipment order strength offsetting procedure concernsFree cash flow acceleration driven by working capital improvements

Risks management surfaced:

Increased tariff costs ($45M for FY26, up $15M from prior guidance)Hospital reimbursement pressure from OB-3 and Medicaid coverage changesMedTech manufacturing relocation creating uncertain capital demand timingEmployee health care benefit cost inflation driven by utilizationBioprocessing customer inventory building creating demand unpredictability

Answers to last quarter's watch list

Tariff mitigation traction — Net tariff impact moved the wrong way, from $30M to $45M, driven by metals tariff escalation (copper, steel, aluminum) since last quarter's print. Mitigation is happening but is being outrun by policy changes.
Resolved negatively
Bioprocessing order pattern — Life Sciences flipped from -6.9% to +5.2% YoY; management called the trajectory "fairly predictable" after four to five months of consistency. Life Sciences capital backlog up over 50% to $111M.
Resolved positively
Healthcare capital equipment execution — Healthcare grew 8.1% with service revenue +13%; total backlog rose to $514.5M from $452.9M, indicating orders continue to build faster than conversion. Capital equipment for the company was $255.5M in the quarter.
Resolved positively
AST segment growth durability — AST grew 12.6%, nearly double the 6–7% segment guide, with AST capital equipment up 46%. Management held the FY guide unchanged citing "general conservatism" and MedTech relocation noise.
Resolved positively
ETO settlement cash timing — No new disclosure on ETO cash timing in the press release; FCF guide was raised to $820M from $770M, suggesting the embedded ~$40M settlement payment is being more than offset by working capital and operational improvements.
Continue monitoring

What to watch into next quarter

Whether tariff exposure breaches $45M — the figure has already moved $15M against the company in one quarter; watch for further metals-tariff or China-tariff escalation that would force an EPS cut

Whether the AST FY guide gets raised — running 12.6% vs. 6–7% guide with backlog building; if Q2 prints another double-digit number, the "general conservatism" excuse becomes harder to sustain

Life Sciences sustained recovery — one quarter at +5.2% confirms the inflection but doesn't establish a trajectory; watch whether the FY guide of 6–7% organic in this segment proves achievable on a full-year basis

Operating margin trajectory — Q1 operating margin of 17.7% versus FY2025 adjusted EBIT margin of 23.2% implies meaningful second-half acceleration is required; watch whether tariff and healthcare cost absorption pressures Q2

FCF $820M durability — Q1 FCF of $327M (~40% of FY guide) is well ahead of seasonal pace; watch whether the $50M raise proves conservative or whether the ETO settlement cash payment lands as a Q3/Q4 drag

Sources

  1. Steris Q1 FY2026 press release, SEC filing: https://www.sec.gov/Archives/edgar/data/1757898/000175789825000007/ste6302025ex991.htm
  2. Steris Q4 FY2025 brief (prior quarter context), Tapebrief archive.

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.